KD-64-A new selective A2A adenosine receptor antagonist has anti-inflammatory activity but contrary to the non-selective antagonist-Caffeine does not reduce diet-induced obesity in mice.
Adenosine A2 Receptor Antagonists
/ pharmacology
Animals
Anti-Inflammatory Agents
/ pharmacology
Body Weight
/ drug effects
Caffeine
/ pharmacology
Capillary Permeability
/ drug effects
Diet
/ adverse effects
Diet, High-Fat
/ adverse effects
Insulin Resistance
Interleukin-6
/ blood
Locomotion
/ drug effects
Male
Mice
Obesity
/ chemically induced
Peritoneum
/ drug effects
Tumor Necrosis Factor-alpha
/ blood
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
02
2020
accepted:
27
05
2020
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
22
8
2020
Statut:
epublish
Résumé
The A2 adenosine receptors play an important role, among others, in the regulation of inflammatory process and glucose homeostasis in diabetes and obesity. Thus, the presented project evaluated of influence of the selective antagonist of A2A adenosine receptor-KD-64 as compared to the known non-selective antagonist-caffeine on these two particular processes. Two different inflammation models were induced namely local and systemic inflammation. Obesity was induced in mice by high-fat diet and the tested compounds (KD-64 and caffeine) were administrated for 21 days. KD-64 showed anti-inflammatory effect in both tested inflammation models and administered at the same dose as ketoprofen exerted stronger effect than this reference compound. Elevated levels of IL-6 and TNF-α observed in obese control mice were significantly lowered by the administration of KD-64 and were similar to the values observed in control non-obese mice. Interestingly, caffeine increased the levels of these parameters. In contrast to caffeine which had no influence on AlaT activity, KD-64 administration significantly lowered AlaT activity in the obese mice. Although, contrary to caffeine, KD-64 did not reduce diet-induced obesity in mice, it improved glucose tolerance. Thus, the activity of the selective adenosine A2A receptor antagonist was quite different from that of the non-selective.
Identifiants
pubmed: 32555600
doi: 10.1371/journal.pone.0229806
pii: PONE-D-20-04266
pmc: PMC7302451
doi:
Substances chimiques
Adenosine A2 Receptor Antagonists
0
Anti-Inflammatory Agents
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
Caffeine
3G6A5W338E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229806Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neuromolecular Med. 2013 Jun;15(2):295-309
pubmed: 23385980
Pulm Pharmacol Ther. 2017 Aug;45:90-94
pubmed: 28499635
Med Sci Sports Exerc. 2007 Sep;39(9):1554-60
pubmed: 17805088
Nat Rev Drug Discov. 2014 Dec;13(12):886-7
pubmed: 25394869
Am J Clin Nutr. 2006 Mar;83(3):674-80
pubmed: 16522916
EMBO Mol Med. 2013 Mar;5(3):413-29
pubmed: 23341106
J Clin Invest. 2017 Jan 3;127(1):1-4
pubmed: 28045402
Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
pubmed: 10092513
Ann Clin Biochem. 2016 Nov;53(6):663-668
pubmed: 26787627
Obes Rev. 2011 Oct;12(10):866-83
pubmed: 21951333
Inflamm Res. 2010 Aug;59(8):635-45
pubmed: 20221667
Front Med. 2013 Mar;7(1):14-24
pubmed: 23471659
Metab Brain Dis. 2016 Oct;31(5):1023-9
pubmed: 27216278
Iran J Pharm Res. 2014 Spring;13(2):707-18
pubmed: 25237367
Arch Pharm (Weinheim). 2011 Jan;344(1):20-7
pubmed: 21213348
Pediatr Res. 2009 Feb;65(2):203-8
pubmed: 19047957
Int J Mol Sci. 2011;12(5):3117-32
pubmed: 21686173
Br J Pharmacol. 2000 Apr;129(7):1465-73
pubmed: 10742303
Mol Aspects Med. 2017 Jun;55:90-101
pubmed: 28104382
Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):357-68
pubmed: 12220549
Clin Hemorheol Microcirc. 2018;68(1):5-15
pubmed: 29439317
Hepatology. 2004 Oct;40(4):933-41
pubmed: 15382116
Acta Neuropathol. 2014 Jan;127(1):3-28
pubmed: 24096619
Eur J Pharmacol. 1997 Feb 26;321(2):143-7
pubmed: 9063681
Inflamm Res. 2008 Jun;57(6):272-8
pubmed: 18516709
Obesity (Silver Spring). 2009 Jun;17(6):1220-5
pubmed: 19282821
J Med Life. 2016 Jul-Sep;9(3):275-279
pubmed: 27974933
Brain Res Mol Brain Res. 1992 Jul;14(3):186-95
pubmed: 1279342
J Thorac Cardiovasc Surg. 2005 May;129(5):1137-43
pubmed: 15867791
Pharmacol Biochem Behav. 2015 Feb 28;132:71-78
pubmed: 25735490
Life Sci. 1997;61(10):951-6
pubmed: 9296333
Vascul Pharmacol. 2010 May-Jun;52(5-6):199-206
pubmed: 20045081
Biomed Pharmacother. 2018 Nov;107:306-328
pubmed: 30098549
J Cell Physiol. 2005 Jan;202(1):9-20
pubmed: 15389588
Eur J Pharmacol. 1999 Dec 15;386(2-3):253-61
pubmed: 10618477
Biochem Pharmacol. 2019 Oct;168:193-203
pubmed: 31295465
J Appl Physiol (1985). 2014 Oct 1;117(7):745-54
pubmed: 25123196
Proc Soc Exp Biol Med. 1962 Dec;111:544-7
pubmed: 14001233
Postepy Hig Med Dosw (Online). 2013 Apr 24;67:331-8
pubmed: 23619233
Int J Obes Relat Metab Disord. 1999 Apr;23(4):425-31
pubmed: 10340822
J Psychiatr Res. 2014 Apr;51:49-59
pubmed: 24433848
Clin Immunol. 2018 Jul;192:68-77
pubmed: 29678503
Nat Rev Drug Discov. 2013 Apr;12(4):265-86
pubmed: 23535933
FASEB J. 2017 Nov;31(11):4985-4997
pubmed: 28765173
Cell Mol Life Sci. 2007 May;64(10):1187-204
pubmed: 17364141
PLoS One. 2015 Nov 05;10(11):e0142078
pubmed: 26539982
Arch Med Sci. 2017 Jun;13(4):851-863
pubmed: 28721154
Metab Brain Dis. 2015 Dec;30(6):1487-94
pubmed: 26419385
Hepatology. 2017 Aug;66(2):616-630
pubmed: 28133767
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
Naunyn Schmiedebergs Arch Pharmacol. 2018 Aug;391(8):875-881
pubmed: 29802412
Neuroscience. 2010 Oct 27;170(3):923-8
pubmed: 20678550
Br J Nutr. 2004 Sep;92(3):347-55
pubmed: 15469638
J Clin Invest. 2001 Apr;107(7):861-9
pubmed: 11285305
Mediators Inflamm. 2015;2015:493409
pubmed: 25944984
Am J Physiol Endocrinol Metab. 2018 May 1;314(5):E433-E447
pubmed: 29118012
Respir Res. 2009 Jun 26;10:58
pubmed: 19558673
J Leukoc Biol. 2008 Mar;83(3):447-55
pubmed: 18160539
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Mar;1864(3):271-280
pubmed: 30553055
Naunyn Schmiedebergs Arch Pharmacol. 2008 Mar;377(1):65-76
pubmed: 18188542
J Lipid Res. 2007 Sep;48(9):1905-14
pubmed: 17699733
Mol Med. 2008 Jul-Aug;14(7-8):485-92
pubmed: 18431463
Eur J Med Chem. 2011 Sep;46(9):3590-607
pubmed: 21664729
Nature. 2014 Dec 18;516(7531):395-9
pubmed: 25317558
J Psychopharmacol. 2019 Dec;33(12):1550-1561
pubmed: 31161847
J Nutr Sci Vitaminol (Tokyo). 2011;57(1):104-7
pubmed: 21512298
Pharmacol Biochem Behav. 2008 May;89(3):345-51
pubmed: 18281083
Fluids Barriers CNS. 2015 Sep 02;12:20
pubmed: 26330053
Gastroenterology. 2007 May;132(6):2169-80
pubmed: 17498510
Endocrinology. 2005 Mar;146(3):1003-5
pubmed: 15713941
Obesity (Silver Spring). 2013 Oct;21(10):1991-6
pubmed: 23686786
Obesity (Silver Spring). 2015 Sep;23(9):1830-5
pubmed: 26239482
Neuroendocrinology. 2000 Jan;71(1):68-78
pubmed: 10644901
Inflamm Res. 2019 Oct;68(10):815-823
pubmed: 31312858
Nat Rev Drug Discov. 2008 Sep;7(9):759-70
pubmed: 18758473
Med Sci Sports Exerc. 2013 Jul;45(7):1269-76
pubmed: 23299767